IL236184A0 - Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat hyperthyroidism - Google Patents

Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat hyperthyroidism

Info

Publication number
IL236184A0
IL236184A0 IL236184A IL23618414A IL236184A0 IL 236184 A0 IL236184 A0 IL 236184A0 IL 236184 A IL236184 A IL 236184A IL 23618414 A IL23618414 A IL 23618414A IL 236184 A0 IL236184 A0 IL 236184A0
Authority
IL
Israel
Prior art keywords
dihydroxyvitamin
methylene
secondary hyperparathyroidism
treat secondary
treat
Prior art date
Application number
IL236184A
Other languages
English (en)
Hebrew (he)
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL236184(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of IL236184A0 publication Critical patent/IL236184A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL236184A 2012-06-29 2014-12-11 Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat hyperthyroidism IL236184A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666264P 2012-06-29 2012-06-29
PCT/US2013/031574 WO2014003849A1 (en) 2012-06-29 2013-03-14 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Publications (1)

Publication Number Publication Date
IL236184A0 true IL236184A0 (en) 2015-01-29

Family

ID=47997980

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236184A IL236184A0 (en) 2012-06-29 2014-12-11 Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat hyperthyroidism

Country Status (19)

Country Link
US (4) US9205096B2 (enExample)
EP (1) EP2866811A1 (enExample)
JP (1) JP2015522015A (enExample)
KR (1) KR20150030673A (enExample)
CN (1) CN104394871A (enExample)
AU (1) AU2013281217B2 (enExample)
BR (1) BR112014032847A2 (enExample)
CA (1) CA2877680C (enExample)
CL (1) CL2014003565A1 (enExample)
CO (1) CO7240358A2 (enExample)
HK (1) HK1206600A1 (enExample)
IL (1) IL236184A0 (enExample)
MX (1) MX2015000076A (enExample)
MY (1) MY172886A (enExample)
NZ (1) NZ703347A (enExample)
RU (1) RU2666995C2 (enExample)
SG (1) SG11201408731WA (enExample)
WO (1) WO2014003849A1 (enExample)
ZA (1) ZA201500119B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY172886A (en) * 2012-06-29 2019-12-13 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
CA2923758C (en) 2013-09-27 2022-08-30 Codexis, Inc. Structure based predictive modeling
CA2923755C (en) 2013-09-27 2023-03-14 Codexis, Inc. Automated screening of enzyme variants
CN103533522A (zh) * 2013-10-25 2014-01-22 从兴技术有限公司 短信稽核的方法及系统
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10369161B2 (en) * 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10105375B2 (en) 2016-08-30 2018-10-23 Wisconsin Alumni Research Foundation Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
CA2404335C (en) 2000-03-27 2009-01-06 Wisconsin Alumni Research Foundation Vitamin d compounds used to stabilize kidney transplants
MXPA03000406A (es) * 2000-07-14 2003-06-06 Wisconsin Alumni Res Found Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
JP2007505882A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク 脆弱、筋損傷又はサルコペニアの治療のための2−アルキリデン−19−ノル−ビタミンd誘導体
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
EP1853274B1 (en) 2005-02-11 2013-01-23 Wisconsin Alumni Research Foundation 2-methylene-19-nor- (20s-24s) - 1alpha, 25-dihydroxyvitamine-d2
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
CA2764577C (en) * 2009-08-03 2017-12-19 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
CA2794006C (en) 2010-03-23 2017-11-28 Wisconsin Alumni Research Foundation (20s)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-hydroxyvitamin d3
MY172886A (en) * 2012-06-29 2019-12-13 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism

Also Published As

Publication number Publication date
HK1206600A1 (en) 2016-01-15
MX2015000076A (es) 2015-04-10
US20140187522A1 (en) 2014-07-03
CA2877680A1 (en) 2014-01-03
BR112014032847A2 (pt) 2017-06-27
JP2015522015A (ja) 2015-08-03
US20160136184A1 (en) 2016-05-19
US9717744B2 (en) 2017-08-01
US9205096B2 (en) 2015-12-08
US9034853B2 (en) 2015-05-19
CO7240358A2 (es) 2015-04-17
CL2014003565A1 (es) 2015-08-28
CN104394871A (zh) 2015-03-04
SG11201408731WA (en) 2015-01-29
US10046000B2 (en) 2018-08-14
AU2013281217B2 (en) 2017-03-02
AU2013281217A1 (en) 2015-01-22
KR20150030673A (ko) 2015-03-20
ZA201500119B (en) 2017-11-29
RU2666995C2 (ru) 2018-09-13
CA2877680C (en) 2017-08-29
WO2014003849A1 (en) 2014-01-03
US20170252360A1 (en) 2017-09-07
RU2015102831A (ru) 2016-08-20
EP2866811A1 (en) 2015-05-06
US20140005152A1 (en) 2014-01-02
NZ703347A (en) 2016-05-27
MY172886A (en) 2019-12-13

Similar Documents

Publication Publication Date Title
ZA201500119B (en) Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
EP2891095A4 (en) EXPERT SYSTEM FOR PREDICTING CHANGES IN LOCAL ENVIRONMENT
ZA201307367B (en) Method of securing non-native code
EP2850718A4 (en) SYSTEM FOR WIRELESS POWER DISTRIBUTION
CO7061082A2 (es) Compuestos para tratar la artrofia muscular espinal
ZA201406073B (en) Tetramerisation of ethylene
BR112014006702A2 (pt) método para tratar osteoporose
GB201201566D0 (en) New chemical compounds
GB201403600D0 (en) Conversion of HF alkylation units for ionic liquid catalyzed alkylation processes
IL236218A (en) Dimethyl-benzoic acid compounds
ZA201505967B (en) Process for the conversion of methoxylated aromatic compounds to simple aromatic compounds
BR112015003935A2 (pt) método para reduzir a demanda de oxigênio químico recalcitrante
ZA201406074B (en) Tetramerisation of ethylene
IL237483A0 (en) Preparations for the treatment of psoriasis
HUE045685T2 (hu) Triacil-glicerideket tartalmazó olajok konverziója
GB201222683D0 (en) Chemical reactor
LT2895177T (lt) Humuso rūgšties panaudojimas šiltakraujų gyvūnų gydymui
EP2804612A4 (en) THERAPEUTIC USES OF TETRACHLORODECAOXYGEN (TCDO)
GB201203430D0 (en) Chemical reaction
IL239429A0 (en) Use of fidotimide to treat psoriasis
EP3240549A4 (en) Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
EP2802549A4 (en) REAKTORPASSIVIERUNGSVERFAHREN
EP2831002A4 (en) TREATMENT PLANT FOR WASTEWATER TREATMENT
IL234440A0 (en) Process for the production of nitroalcohols
PL2821794T3 (pl) Sposób mieszania roztworu